Centre for Human Drug Research

We are expanding! Yesterday we have signed a cooperation agreement with the regional hospital Medisch Spectrum Twente (MST) and TechMed Centre - University of Twente (UT) for our new location in Twente. Geert Jan Groeneveld, CEO CHDR: “We are looking forward to establishing a presence in Twente and carrying out technically innovative clinical drug research in close collaboration with MST and UT. Collaboration between a major hospital, a university of technology and an institute conducting phase 1 drug research is unique, so this is a hugely exciting step!” Read more here: https://lnkd.in/eAZzp-5N

We are thrilled to announce that we are among the winners of the 2024 CRO Leadership awards! Based on research from ISR’s Contract Research Organization Quality Benchmarking annual online survey, 42 contract research organizations were evaluated on more than 20 different performance metrics. CHDR is among the champions for compatibility, therapeutic expertise, data quality, and reliability! At CHDR, we believe in continuously pushing the boundaries to deliver outstanding results for our clients. This award is a testament to the hard work and dedication of our entire team. We are grateful for the support of our partners and clients, and we will continue to strive for excellence in everything we do. Here's to many more milestones and successes together! https://lnkd.in/dj-M_hk

We are proud to share the results of a phase 1 clinical trial in patients with Parkinson's disease, published in Nature Medicine. This patient study, conducted in collaboration with Vaxxinity and the The Michael J. Fox Foundation for Parkinson's Research, demonstrates that UB-312 is the first drug candidate to produce a demonstrable immunological response in patients. UB-312 is a form of active immunotherapy that targets the aggregated protein α-synuclein (aSN), which plays an important role in Parkinson's disease. UB-312 not only proved to be safe and well tolerated, but also reached its target: anti-aSN antibodies were found in the cerebrospinal fluid, accompanied by a significant reduction in the concentration of aggregated aSN. These results mark a milestone in the search for new treatments for Parkinson's disease and support the further development of UB-312. Read the paper here: https://lnkd.in/ghwXYSVx #nature #clinicalresearch #clinicaltrials #parkinson's

Join us for the Dutch Bio Science Week on 22-29 June 2024! As part of the Dutch Bio Science Week programme, CHDR is opening its doors to everyone interested in learning more about the work we do. On Saturday 29 June from 10:00-15:00, you will be able to take a tour through our building, have a demonstration of some of the tests we use to show drug effects, and much more (including activities for children). Sign up here: https://lnkd.in/dv8SW-jT About Dutch Bio Science Week 2024: Dutch Bio Science Week is an eight-day action-packed programme, inviting everyone from age 4 to 104 to come and discover how groundbreaking innovations are shaping the future of our health. #DBSW24 takes place in Leiden and is a joint initiative by Leiden Bio Science Park in collaboration with Leiden Kennisstad, Leiden Healthy Society Centre, Leiden & Partners and many partners in the Life Science & Health ecosystem. Visit www.dutchbioscienceweek.nl for the entire programme.

A great week for science! On the 12th of June Eva Thijssen successfully defended her PhD thesis, and on the 13th of June Ahnjili ZhuParris, Ph.D successfully defended hers. Congratulations to both of them on this great accomplishment! Read their thesis here: https://lnkd.in/d8xihWiH

Last weekend our colleagues participated in the Leiden Marathon. Team CHDR ran half a marathon and raised money for Xenia Hospice. At Xenia, a safe and pleasant environment is provided for young people who need intensive medical care. CHDR was happy to sponsor the team!

The HagaZiekenhuis and the Centre for Human Drug Research (CHDR) collaborate structurally in the fields of scientific research and education. The CHDR conducts high-quality pharmaceutical research, while the HagaZiekenhuis is a large STZ teaching hospital where many patients are treated. By joining forces, both institutions can conduct pharmaceutical research at the HagaZiekenhuis. After an intensive preparatory period, the first joint research has commenced. The research focuses on advanced measurements that can be used to map memory loss due to early-stage dementia. Both the CHDR and the HagaZiekenhuis are delighted with the start of the collaboration and anticipate initiating many more joint projects in the coming years. Stay tuned for updates! ------------------------------------------------------------------------------- Het HagaZiekenhuis en het Centre for Human Drug Research (CHDR) werken structureel samen op het gebied van wetenschappelijk onderzoek en opleidingen. Het CHDR voert hoogwaardig geneesmiddelenonderzoek uit, terwijl het HagaZiekenhuis een groot STZ-opleidingsziekenhuis is waar veel patiënten worden behandeld. Door onze krachten te bundelen, kunnen beide instellingen geneesmiddelenonderzoek uitvoeren bij patiënten in het HagaZiekenhuis. Na een intensieve voorbereidingsperiode is het eerste gezamenlijke onderzoek van start gegaan. Het onderzoek richt zich op geavanceerde metingen die gebruikt kunnen worden om geheugenverlies door beginnende dementie in kaart te brengen. Zowel het CHDR als het HagaZiekenhuis zijn zeer verheugd over de start van de samenwerking en verwachten in de komende jaren nog veel meer gezamenlijke projecten op te starten. Houd ons in de gaten voor updates! https://lnkd.in/gReGhhD6

CHDR zoekt nieuwe arts-onderzoekers! Heb je altijd al een diepgaande interesse gehad in de werking van geneesmiddelen en de ontwikkeling ervan? Wil je actief bijdragen aan het onderzoek en de ontwikkeling van nieuwe geneesmiddelen? Als arts-onderzoeker bij CHDR krijg je de kans om betrokken te zijn bij het opzetten, uitvoeren en publiceren van klinisch geneesmiddelonderzoek. Momenteel is CHDR opzoek naar arts-onderzoekers die willen promoveren in de richtingen immunologie of psychofarmacologie. Wat is jouw rol als arts-onderzoeker bij CHDR? - Je bent werkzaam als projectleider van klinische studies; je bereidt samen met het team de klinische studies voor, voert ze uit en analyseert de resultaten; - Je bent als studiearts medisch verantwoordelijk voor de veiligheid en welzijn van proefpersonen; - Je publiceert wetenschappelijke artikelen, zowel in samenwerking met farmaceutische bedrijven als eigen onderzoek; - Je neemt deel aan (inter)nationale congressen; - Je krijgt de mogelijkheid om je te certificeren tot klinisch farmacoloog bij de Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie (NVKFB). Lisa Pagan vertelt graag veel meer over hoe het is om bij CHDR als arts-onderzoeker te werken: https://lnkd.in/gPRsPBKP Ben jij geïnteresseerd in de werking van geneesmiddelen en zoek jij een inspirerende en uitdagende promotieplaats? Neem een kijkje op onze website of stuur een bericht naar Noa Zeelenberg. 

Congratulations to Gert-Jan Hassing for successfully defending his PhD thesis entitled 'Feasibility of interpreting blinded pharmacodynamic data - normal variations in healthy subjects' on the 23rd of April! Read more here: https://lnkd.in/evvE-TcU

We proudly present our 2023 annual report, structured around our three strategic goals — developing drugs, developing methods and developing people. Alongside this, the reports includes a range of other stories from around the organisation, celebrating the diverse efforts of our operational and scientific staff. This year's theme is 'Bridging the Gap'. It has always been our core business to build bridges between preclinical and clinical drug development, and between studies in healthy participants and in patients. The theme is also about building bridges between academic researchers and between academia and pharmaceutical companies. Read about how we bridged the gap in 2023 here: https://lnkd.in/e-Hq3hth